{
  "sop_id": "acme-SOP-SPECIALTY-BIO-20250318.4",
  "title": "Specialty Biologic Medication Prior Authorization Process",
  "version": "4.2",
  "effective_date": "2025-03-18",
  "review_date": "2025-09-18",
  "department": "Pharmacy Benefits Management",
  "status": "ACTIVE",
  "applicable_plans": [
    "acme-SPECIALTYPLUS-2025",
    "acme-STANDARD-2025",
    "acme-VALUECARE-2025"
  ],
  "applicable_medications": [
    {
      "category": "TNF Inhibitors",
      "drugs": [
        "infliximab",
        "adalimumab",
        "etanercept",
        "golimumab",
        "certolizumab"
      ]
    },
    {
      "category": "Interleukin Inhibitors",
      "drugs": [
        "ustekinumab",
        "secukinumab",
        "ixekizumab",
        "risankizumab"
      ]
    }
  ],
  "purpose": "This SOP establishes the standardized process for reviewing and determining medical necessity for specialty biologic medications requiring prior authorization under acme pharmacy benefit plans.",
  "scope": "Applies to all specialty biologic medications administered by subcutaneous injection or intravenous infusion for autoimmune and inflammatory conditions.",
  "definitions": [
    {
      "term": "PA",
      "definition": "Prior Authorization"
    },
    {
      "term": "TNF",
      "definition": "Tumor Necrosis Factor"
    },
    {
      "term": "DMARD",
      "definition": "Disease-Modifying Anti-Rheumatic Drug"
    }
  ],
  "roles_and_responsibilities": [
    {
      "role": "Pharmacy Technician",
      "responsibilities": [
        "Initial documentation gathering",
        "Administrative review",
        "Claim routing"
      ],
      "authority_level": 1
    },
    {
      "role": "Clinical Pharmacist",
      "responsibilities": [
        "Clinical appropriateness review",
        "Step therapy evaluation",
        "Initial determination"
      ],
      "authority_level": 2
    },
    {
      "role": "Medical Director",
      "responsibilities": [
        "Complex case review",
        "Exception approvals",
        "Final determinations"
      ],
      "authority_level": 3
    }
  ],
  "procedure_steps": [
    {
      "step_number": 1,
      "title": "Claim Receipt and Validation",
      "description": "Verify claim contains all required elements for processing.",
      "actions": [
        "Confirm patient demographics and eligibility",
        "Verify claim includes diagnosis code(s)",
        "Confirm NDC or HCPCS code is present",
        "Validate prescriber information"
      ],
      "timeframe": "24 hours from receipt",
      "required_fields": [
        "member_id",
        "diagnosis_code",
        "drug_code",
        "prescriber_npi"
      ],
      "escalation_path": "Incomplete claims routed to Exception Queue"
    },
    {
      "step_number": 2,
      "title": "Benefit Verification",
      "description": "Confirm patient's plan covers requested medication and determine authorization requirements.",
      "actions": [
        "Check formulary status of medication",
        "Determine tier level and patient cost-share",
        "Identify any quantity limits or duration restrictions",
        "Verify site-of-care requirements"
      ],
      "timeframe": "24 hours from validation",
      "system_access": [
        "Formulary Database",
        "Benefits Platform",
        "Coverage Policy Database"
      ],
      "output": "Benefit Verification Summary"
    },
    {
      "step_number": 3,
      "title": "Clinical Criteria Evaluation",
      "description": "Review clinical documentation to assess medical necessity according to acme coverage criteria.",
      "actions": [
        "Verify diagnosis is FDA-approved or supported by clinical guidelines",
        "Confirm required baseline testing is documented",
        "Evaluate prior treatment history against step therapy requirements",
        "Assess dosing against weight-based guidelines"
      ],
      "decision_logic": {
        "approval_criteria": [
          "Diagnosis is FDA-approved or supported by NCCN/ACR guidelines",
          "Required prior therapies have been tried for minimum duration",
          "Documentation of inadequate response to prior therapies",
          "No contraindications to requested therapy",
          "Dosing within approved range for indication and weight"
        ],
        "denial_criteria": [
          "Non-approved diagnosis without supporting literature",
          "Required step therapy not attempted",
          "Contraindication to requested therapy exists",
          "Dosing exceeds maximum approved limits"
        ],
        "exception_criteria": [
          "Documented adverse reaction to required prior therapy",
          "Documented contraindication to all step therapy options",
          "Rapid disease progression requiring immediate biologic therapy"
        ]
      },
      "timeframe": "72 hours from benefit verification",
      "escalation_trigger": "Any case not meeting straightforward approval/denial criteria"
    }
  ],
  "indications_and_criteria": [
    {
      "indication": "Rheumatoid Arthritis",
      "icd10_codes": [
        "M05.1",
        "M05.2",
        "M05.3",
        "M05.9",
        "M06.9"
      ],
      "approval_criteria": [
        "Moderate to severe disease (CDAI > 10 or DAS28 > 3.2)",
        "Prior treatment with methotrexate for ≥ 12 weeks unless contraindicated",
        "If methotrexate contraindicated, prior trial of leflunomide or sulfasalazine",
        "Documentation of active inflammation (elevated CRP/ESR or synovitis on exam)"
      ],
      "duration_of_approval": "Initial: 6 months, Renewal: 12 months",
      "renewal_criteria": [
        "Documentation of clinical improvement (reduction in CDAI score ≥ 10 points or DAS28 improvement ≥ 1.2)",
        "No serious adverse events requiring discontinuation"
      ]
    },
    {
      "indication": "Crohn's Disease",
      "icd10_codes": [
        "K50.00",
        "K50.10",
        "K50.80",
        "K50.90"
      ],
      "approval_criteria": [
        "Moderate to severe disease (CDAI > 220 or fecal calprotectin > 250 μg/g)",
        "Prior treatment with corticosteroids and one immunomodulator (azathioprine, 6-MP, or methotrexate)",
        "Documentation of active inflammation (elevated CRP/ESR, endoscopic evidence, or imaging)",
        "For fistulizing disease: presence of draining enterocutaneous or perianal fistula(s)"
      ],
      "duration_of_approval": "Initial: 6 months, Renewal: 12 months",
      "renewal_criteria": [
        "Documentation of clinical improvement (reduction in CDAI score ≥ 70 points or 50% reduction in fistula drainage)",
        "No serious adverse events requiring discontinuation"
      ]
    }
  ],
  "state_specific_requirements": [
    {
      "state": "IL",
      "requirements": [
        "PA determination must be issued within 72 hours (24 hours for urgent requests)",
        "Step therapy exceptions must be granted for documented adverse events",
        "Written notification required for all denials including appeal rights"
      ],
      "regulatory_citations": [
        "215 ILCS 5/356z.35",
        "Illinois Admin Code Title 50, Ch. I, Part 2026"
      ]
    },
    {
      "state": "CA",
      "requirements": [
        "PA determination must be issued within 72 hours (24 hours for urgent requests)",
        "External review option required for all denials",
        "Exception process required for non-formulary medications"
      ],
      "regulatory_citations": [
        "CA Health & Safety Code § 1367.241",
        "CA Insurance Code § 10123.191"
      ]
    }
  ],
  "documentation_requirements": [
    "Current chart notes documenting diagnosis",
    "Lab results supporting diagnosis and disease activity",
    "Treatment history including dates, doses, and response",
    "Current weight for weight-based dosing calculations",
    "TB test results within past 12 months",
    "Hepatitis B screening results"
  ],
  "references": [
    {
      "title": "American College of Rheumatology Treatment Guidelines",
      "url": "https://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines",
      "last_updated": "2024-01-15"
    },
    {
      "title": "American Gastroenterological Association Guidelines",
      "url": "https://gastro.org/guidelines/",
      "last_updated": "2023-11-30"
    }
  ],
  "attachments": [
    {
      "title": "Specialty Medication Prior Authorization Form",
      "file_id": "FORM-PA-SPECIALTY-2025-1"
    },
    {
      "title": "Step Therapy Exception Request Form",
      "file_id": "FORM-ST-EXCEPTION-2025-1"
    }
  ],
  "revision_history": [
    {
      "version": "4.2",
      "date": "2025-03-18",
      "author": "Maria Rodriguez, PharmD",
      "changes": "Updated IL state requirements to comply with new legislation effective March 1, 2025"
    },
    {
      "version": "4.1",
      "date": "2024-12-10",
      "author": "David Chen, PharmD",
      "changes": "Added risankizumab to covered IL inhibitors; updated dosing guidelines for pediatric Crohn's disease"
    }
  ]
}
